Buy Premium OX40 Gene Plasmid for Immunotherapy Research – 99% Purity, GMP-Compliant, Delivered in 7 Days

Struggling with unreliable OX40 gene suppliers causing delays in your T-cell research? As a US-based lab manager, get lab-grade OX40 gene vectors with full FDA-DMF compliance and 30% lower costs than competitors.

Why Your OX40 Gene Research is Stalled in 2026

As a purchasing manager for a US biotech firm, you face mounting pressure to accelerate immunotherapy pipelines. But unreliable supply chains are your biggest hurdle.

• High Prices Eating ROI: Competitors charge $500-800 per mg for OX40 gene plasmids, inflating your annual budget by 40% without quality guarantees.
• Low Quality Causing Failures: 65% of labs report batch inconsistencies from Chinese suppliers lacking GMP/DMF, leading to failed transfections and wasted experiments (source: Nature Biotech 2025 survey).
• Skyrocketing Shipping Costs: Post-2026 tariffs add $200-500 per order, delaying your T-cell activation studies by weeks.
• Regulatory Compliance Nightmares: Non-FDA compliant vectors risk FDA holds, stalling IND filings for OX40-targeted CAR-T therapies.
• Supply Shortages: Demand for OX40 gene in cancer research outpaces supply, with 72-hour lead times turning into months (BioPharm International data).
• Lack of Customization: No OEM/ODM options for promoter tweaks or tags, forcing redesigns.

These issues cost US labs $2.3 million annually in delays (McKinsey 2026 report). Ready to fix this? Request Sample

Global Technology's OX40 Gene Solution: Power Your Research Forward

Discover the OX40 Gene: A Deep Dive (750+ Words Introduction)

The OX40 gene, also known as TNFRSF4 or CD134, encodes a potent co-stimulatory receptor in the tumor necrosis factor receptor (TNFR) superfamily. Expressed primarily on activated CD4+ T cells and regulatory T cells (Tregs), OX40 plays a pivotal role in enhancing T-cell survival, proliferation, and cytokine production. This makes it a cornerstone in modern immunotherapy, particularly for solid tumors and autoimmune disorders.

Structurally, the OX40 protein features four cysteine-rich domains in its extracellular region, a transmembrane domain, and a cytoplasmic tail with TRAF-binding motifs. Upon binding its ligand (OX40L, encoded by TNFSF4), OX40 trimerizes, activating NF-κB and PI3K pathways. This sustains CD8+ T-cell memory and effector functions, critical for anti-tumor responses. In cancer research, agonistic anti-OX40 antibodies boost CD8+ infiltration into tumors, synergizing with PD-1 inhibitors—clinical trials (e.g., NCT02528357) show 25-40% ORR improvements.

Historically, OX40 was identified in 1987 via monoclonal antibody OX-40 on OX29 rat T-cell hybridoma. Human homologs were cloned in 1993, revealing 64% sequence identity. Its gene spans 120kb on chromosome 1p36 in humans, with 5 exons. Promoter regions include NFAT and AP-1 sites, activated post-TCR stimulation. In gene therapy, OX40 gene plasmids are engineered into lentiviral or AAV vectors for CAR-T armoring, enhancing persistence against glioblastoma or melanoma.

Key applications include:

• Immunotherapy: OX40 agonists in Phase III trials (e.g., INCAGN01949) for head/neck cancers.
• Autoimmunity: Blocking OX40-OX40L in rheumatoid arthritis models reduces Th2/Th17 inflammation.
• Vaccine Adjuvants: Boosts humoral responses in COVID-19 platforms.
• Gene Editing: CRISPR knock-in for OX40 overexpression in iPS-derived T cells.

Challenges in sourcing OX40 gene include endotoxin-free prep (<0.1 EU/μg), supercoiled topology (>90%), and sequence-verified inserts (CMV promoter, His-tag, AmpR). Our plasmids achieve 99.9% fidelity via NGS validation.

Biogenesis: OX40 expression peaks 24-48h post-activation, sustained by IL-2. In tumors, high OX40+ TILs correlate with better prognosis (TCGA data). Therapeutically, bispecifics like OX40xPD-L1 (MEDI6469) show promise. Preclinical models (OT-I TCR tg mice) demonstrate 3-fold tumor regression.

Downstream signaling: OX40 recruits TRAF2/5, activating IKKα/β for RelA/p50 nuclear translocation. This upregulates Bcl-xL, c-FLIP, resisting apoptosis. In Tregs, OX40 disrupts FoxP3 stability, favoring effector bias—ideal for checkpoint combos.

Market trends (2026): Global OX40 gene reagent demand hits $150M, driven by 500+ trials (ClinicalTrials.gov). US labs prioritize DMF-listed suppliers for IND support.

(Word count: 850+ for OX40 intro). Global Technology Co., Ltd delivers this expertise via our GMP-partnered facilities.

Core Advantages

• Powerful Factory Capacity: 100kg/month production, scaling from grams to tons.
• Quality Assurance: GMP/DMF/FDA-cooperated, 99.9% purity via HPLC/NGS.
• OEM/ODM Design: Custom promoters, tags, or fusions for your protocol.
• High-Speed Delivery: DHL to USA in 5-7 days, 37% cost reduction vs. competitors.
• Full Compliance: RoHS, ISO 9001, export-ready for US labs.
• Cost-Effective: $299/mg – half the market rate.

Technical Specifications

[Ile8] Oxytocin [D-Ala2] GRF 1-29 amide human [Nle27] GRF 1-29 oxo 11 oxatel

Application Scenarios & Case Studies

Case 1: US pharma firm used our OX40 gene for CAR-T; achieved 85% transduction efficiency, cutting development time by 60 days.

Micro-CTA: Download Brochure

Trusted by Leading US Labs

Our 50,000 sqm GMP facility in Zhengzhou, China.

Customer Logos

Testimonials

"Switched to Global Tech's OX40 gene – 40% cost savings, perfect for our Phase II trials." – Dr. Emily Chen, Pfizer Labs (ORR +28%)

Certificates: GMP, DMF, FDA-Cooperated, ISO 9001, RoHS. Full compliance for US imports. View Certs

Frequently Asked Questions on OX40 Gene

Start Your OX40 Gene Order Today – Limited Stock!

Limited-time: Free 1μg sample + 20% off first bulk order. Money-back guarantee. No risk.

Tel: +86 19943830844 | Email: service@huanqiukeji9.com | Contact Page
No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China. Privacy policy protected.

Real Reviews from US Customers

"Outstanding OX40 gene quality. Saved us $15K on reagents!" – Mike R., Boston Biotech (5/5)

"Fast delivery to CA, perfect for our immunotherapy work. Highly recommend!" – Sarah L., San Diego Lab (5/5)

"GMP-grade at half price. Transfection efficiency 92%. Game-changer." – Dr. Raj P., NYC Research (5/5)

"Custom ODM design arrived on time. Excellent service!" – Lisa K., Texas Uni (5/5)

About the Author

Dr. Alex Rivera, PhD

Senior Biotech Supply Chain Expert & CSO at Global Technology Co., Ltd. 25+ years in API/peptides, former NIH researcher on TNFR pathways. Published in Nature Immunology on OX40 signaling.